G
Gerald Rosen
Researcher at Cedars-Sinai Medical Center
Publications - 118
Citations - 8158
Gerald Rosen is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Sarcoma & Primary tumor. The author has an hindex of 43, co-authored 115 publications receiving 7924 citations. Previous affiliations of Gerald Rosen include UCLA Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Preoperative Chemotherapy for Osteogenic Sarcoma: Selection of Postoperative Adjuvant Chemotherapy Based on the Response of the Primary Tumor to Preoperative Chemotherapy
Gerald Rosen,Brenda Caparros,Andrew G. Huvos,Cynthia Kosloff,Anita Nirenberg,Adrienne Cacavio,Ralph C. Marcove,Joseph M. Lane,Bipin M. Mehta,Christian Urban +9 more
TL;DR: The value of thorough histologic examination in predicting survival in responding patients and in helping identify patients whose disease‐free survival rate can be substantially increased if they are given alternative postoperative adjuvant chemotherapy after failing to have a good response to preoperative chemotherapy are demonstrated.
Journal ArticleDOI
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Paul A. Meyers,Glenn Heller,John H. Healey,Andrew G. Huvos,Joseph M. Lane,Ralph C. Marcove,A. Applewhite,Vaia Vlamis,Gerald Rosen +8 more
TL;DR: Intensive chemotherapy can achieve DFS for a high proportion of patients with osteogenic sarcoma and histologic response to preoperative chemotherapy cannot be assessed at diagnosis, although it is a powerful predictor of DFS.
Journal ArticleDOI
Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.
Gerald Rosen,Ralph C. Marcove,Brenda Caparros,Anita Nirenberg,Cynthia Kosloff,Andrew G. Huvos +5 more
TL;DR: Twenty additional patients with biopsy proven osteogenic sarcoma have been treated with more aggressive preoperative chemotherapy for approximately 2 1/2 months prior to definitive surgery (resection or amputation) and all 20 patients are surviving free of active disease at this brief follow‐up period of 4–20 months.
Journal ArticleDOI
Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma.
TL;DR: Preliminary results indicate that with the use of aggressive chemotherapy, it is possible to demonstrate objective tumor regression in primary osteogenic sarcoma, allowing the surgeon to perform en bloc resection of tumor and prosthetic replacement of the involved bone.
Journal ArticleDOI
Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas
Fritz C. Eilber,Gerald Rosen,Jeffery J. Eckardt,Charles Forscher,Scott D. Nelson,Michael T. Selch,Frederick J. Dorey,Frederick R. Eilber +7 more
TL;DR: Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas.